The frontrunners in a crowded race to develop the first vaccine for respiratory syncytial virus (RSV) — pharmaceutical giants Pfizer and GSK — will face scrutiny from a panel of U.S. experts this week. The company's shots could be the first approved vaccines for the virus, which leads to 3. #cbc | top stories news #ifttt